Salarius Pharmaceuticals
Houston
About Salarius Pharmaceuticals
Salarius Pharmaceuticals is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $58.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:SLRX
- Website: salariuspharma.com
- Phone: +1 346-772-0346
Industries & Categories
Biotechnology, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/salarius-pharmaceuticals-74653 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.